Global Leader In Press Release Distribution And Regulatory Disclosure
Contributor's Links: BusinessWire.com

Business Wire, a Berkshire Hathaway subsidiary, is a company that disseminates full-text news releases from thousands of companies and organizations worldwide to news media, financial markets, disclosure systems, investors, information web sites, databases, bloggers, social networks and other ... more

ALL CONTRIBUTIONS

Walgreens Boots Alliance Fiscal 2021 Second Quarter Results Exceed Expectations
Walgreens Boots Alliance, Inc. today announced financial results for the second quarter of fiscal 2021, which ended Feb. 28, 2021.
Read
REX American Resources Reports Fiscal 2020 Fourth Quarter Results
REX American Resources Corporation today reported financial results for its fiscal 2020 fourth quarter (“Q4 ‘20”) ended January 31, 2021.
Read
ADC Therapeutics Reports Fourth Quarter And Year-End 2020 Financial Results And Provides Business Updates
ADC Therapeutics SA, today reported financial results for the fourth quarter and fiscal year ended December 31, 2020, and provided business updates. 
Read
Moderna Reports Fourth Quarter And Fiscal Year 2020 Financial Results And Provides Business Updates
Moderna, Inc. a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today reported financial results and provided business updates for the fourth quarter and fiscal year 2020, and highlighted pipeline progress.
Read
Alnylam Launches “Alnylam P5x25” Strategy For Planned Transition To A Top Five Biotech In Market Capitalization Over Next Five Years
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced its new five-year strategy, “Alnylam P5x25,” which is focused on the company’s transition to a top-5 biotech (measured by market capitalization) in the next five years.
Read
Gilead Sciences To Acquire Immunomedics
Gilead Sciences, Inc. and Immunomedics announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Immunomedics for $88.00 per share. The transaction values Immunomedics at approximately $21 billion.
Read

STOCKS I FOLLOW

TWEETS

PERSONAL BLOG

Latest Posts

Work Experience

Education

Publications